It has been previously demonstrated that a decrease in PPAR-alpha levels was observed in the lesional skin of patients with psoriasis [76] and that topical PPAR-alpha agonist application decreased TNF-α and IL-1α in the skin [77]. Here, TNF is linked to psoriasis.